BSI-093

N/A

Report date: 2026/05/09 20:00:18

Base Information

Drug NameBSI-093

Drug Alias NameBSI-093

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionAnti-Butyrophilin subfamily 3 member A1

TargetsButyrophilin subfamily 3 member A1

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBiosion Inc

China Registration ClassN/A

Active CompaniesBiosion Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

ATC CodeN/A